KRAS and cancer: This was demonstrated by the application of the integrative analysis of phosphoproteome and drug sensitivity generated for a group of KRAS-mutant cancer cell lines with distinct biological, clinical, and therapeutic characteristics, representative of tumors with the poorest prognosis.